SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Wills Stephen T – ‘4’ for 6/22/22 re: Palatin Technologies Inc.

On:  Friday, 6/24/22, at 7:32pm ET   ·   For:  6/22/22   ·   Accession #:  1654954-22-8784   ·   File #:  1-15543

Previous ‘4’:  ‘4’ on / for 8/13/21   ·   Next:  ‘4’ on 6/28/22 for 6/24/22   ·   Latest:  ‘4’ on 2/2/24 for 1/31/24

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/24/22  Wills Stephen T                   4                      1:12K  Palatin Technologies Inc.         Blueprint/FA

Statement of Changes in Beneficial Ownership of Securities by an Insider   —   Form 4   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 4           Statement of Changes in Beneficial Ownership of     HTML      3K 
                Securities by an Insider -- section16.xml/3.6


        

This ‘4’ Document is an XML Data File that may be rendered in various formats:

  Form 4    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 
 
XML Data rendering:  Statement of Changes in Beneficial Ownership of Securities by an Insider
 
                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<ownershipDocument>
<schemaVersion> X0306 </schemaVersion>
<documentType> 4 </documentType>
<periodOfReport> 2022-06-22 </periodOfReport>
<issuer>
<issuerCik> 0000911216 </issuerCik>
<issuerName> PALATIN TECHNOLOGIES INC </issuerName>
<issuerTradingSymbol> PTN </issuerTradingSymbol>
</issuer>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik> 0001103883 </rptOwnerCik>
<rptOwnerName> WILLS STEPHEN T </rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerStreet1> PALATIN TECHNOLOGIES, INC. </rptOwnerStreet1>
<rptOwnerStreet2> 4B CEDAR BROOK DRIVE </rptOwnerStreet2>
<rptOwnerCity> CRANBURY </rptOwnerCity>
<rptOwnerState> NJ </rptOwnerState>
<rptOwnerZipCode> 08512 </rptOwnerZipCode>
<rptOwnerStateDescription></rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector> false </isDirector>
<isOfficer> true </isOfficer>
<isTenPercentOwner> false </isTenPercentOwner>
<isOther> false </isOther>
<officerTitle> Executive VP and CFO/COO </officerTitle>
</reportingOwnerRelationship>
</reportingOwner>
<nonDerivativeTable>
<nonDerivativeTransaction>
<securityTitle>
<value> Common Stock </value>
</securityTitle>
<transactionDate>
<value> 2022-06-22 </value>
</transactionDate>
<transactionCoding>
<transactionFormType> 4 </transactionFormType>
<transactionCode> A </transactionCode>
<equitySwapInvolved> false </equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value> 395000 </value>
<footnoteId id="F1"/>
</transactionShares>
<transactionPricePerShare>
<value> 0 </value>
<footnoteId id="F1"/>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value> A </value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value> 9109100 </value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
<nonDerivativeTransaction>
<securityTitle>
<value> Common Stock </value>
</securityTitle>
<transactionDate>
<value> 2022-06-22 </value>
</transactionDate>
<transactionCoding>
<transactionFormType> 4 </transactionFormType>
<transactionCode> A </transactionCode>
<equitySwapInvolved> false </equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value> 47457 </value>
<footnoteId id="F2"/>
</transactionShares>
<transactionPricePerShare>
<value> 0 </value>
<footnoteId id="F2"/>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value> A </value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value> 9156557 </value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
<nonDerivativeTransaction>
<securityTitle>
<value> Common Stock </value>
</securityTitle>
<transactionDate>
<value> 2022-06-22 </value>
</transactionDate>
<transactionCoding>
<transactionFormType> 4 </transactionFormType>
<transactionCode> A </transactionCode>
<equitySwapInvolved> false </equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value> 127414 </value>
<footnoteId id="F3"/>
</transactionShares>
<transactionPricePerShare>
<value> 0 </value>
<footnoteId id="F3"/>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value> A </value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value> 9283971 </value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
<nonDerivativeTransaction>
<securityTitle>
<value> Common Stock </value>
</securityTitle>
<transactionDate>
<value> 2022-06-22 </value>
</transactionDate>
<transactionCoding>
<transactionFormType> 4 </transactionFormType>
<transactionCode> A </transactionCode>
<equitySwapInvolved> false </equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value> 36028 </value>
<footnoteId id="F4"/>
</transactionShares>
<transactionPricePerShare>
<value> 0 </value>
<footnoteId id="F4"/>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value> A </value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value> 9319999 </value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
</nonDerivativeTable>
<derivativeTable>
<derivativeTransaction>
<securityTitle>
<value> Stock Option (Right to Buy) </value>
</securityTitle>
<conversionOrExercisePrice>
<value> 0.29 </value>
</conversionOrExercisePrice>
<transactionDate>
<value> 2022-06-22 </value>
</transactionDate>
<transactionCoding>
<transactionFormType> 4 </transactionFormType>
<transactionCode> A </transactionCode>
<equitySwapInvolved> false </equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value> 587500 </value>
</transactionShares>
<transactionPricePerShare>
<value> 0 </value>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value> A </value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<exerciseDate>
<value> 2026-06-22 </value>
<footnoteId id="F5"/>
</exerciseDate>
<expirationDate>
<value> 2032-06-22 </value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value> Common Stock </value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value> 587500 </value>
</underlyingSecurityShares>
</underlyingSecurity>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value> 587500 </value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
</ownershipNature>
</derivativeTransaction>
<derivativeTransaction>
<securityTitle>
<value> Stock Option (Right to Buy) </value>
</securityTitle>
<conversionOrExercisePrice>
<value> 0.58 </value>
</conversionOrExercisePrice>
<transactionDate>
<value> 2022-06-22 </value>
</transactionDate>
<transactionCoding>
<transactionFormType> 4 </transactionFormType>
<transactionCode> A </transactionCode>
<equitySwapInvolved> false </equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value> 211136 </value>
</transactionShares>
<transactionPricePerShare>
<value> 0 </value>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value> A </value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<exerciseDate>
<value> 2022-06-22 </value>
<footnoteId id="F6"/>
</exerciseDate>
<expirationDate>
<value> 2030-06-22 </value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value> Common Stock </value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value> 211136 </value>
</underlyingSecurityShares>
</underlyingSecurity>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value> 211136 </value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
</ownershipNature>
</derivativeTransaction>
</derivativeTable>
<footnotes>
<footnote id="F1"> Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2023. </footnote>
<footnote id="F2"> Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. </footnote>
<footnote id="F3"> Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. </footnote>
<footnote id="F4"> Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 22, 2021, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. </footnote>
<footnote id="F5"> The options vest at the rate of 25% per year, starting on June 22, 2023. </footnote>
<footnote id="F6"> Stock options granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. The performance condition stock option grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. </footnote>
</footnotes>
<ownerSignature>
<signatureName> /s/ Stephen T. Wills by Stephen A. Slusher, Attorney-in-Fact </signatureName>
<signatureDate> 2022-06-24 </signatureDate>
</ownerSignature>
</ownershipDocument>


↑Top
Filing Submission 0001654954-22-008784   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 15, 2:36:24.2pm ET